News

Press Release | Mar 10, 2020

Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue Shield of Massachusetts with over 3 million members in Massachusetts and across New England. The contract expands Interpace’s ThyGeNEXT® and ThyraMIR® thyroid assays as both covered services and now in-network services for BCBS

Press Release | Mar 02, 2020

Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the company’s ThyGeNEXT® and ThyraMIR® tests in the Journal of the American Society of Cytopathology. The article, entitled “Clinical performance of multiplatform mutation panel and microRNA risk classifier in indeterminate thyroid nodules”, will be published online in the

Press Release | Feb 24, 2020

Interpace Biosciences, Inc. (IDXG) announced today that its agreement with LabCorp® (LH) has been extended for an additional two years, through January 2022. Interpace and LabCorp initially entered in to their collaboration in 2016 through which LabCorp became the first national laboratory in the U.S. to offer electronic ordering and result reporting for Interpace’s proprietary

Press Release | Feb 20, 2020

The dietary supplement industry now has a state-of-the-art solution for ensuring supply chain transparency and reassuring consumers that what’s listed on an ingredient panel is actually in their product. As a developer of patented and trademarked ingredients, Nutrition21 has introduced this solution with the adoption of CertainT, which is designed to protect the intellectual property

Press Release | Feb 11, 2020

Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement for Interpace Diagnostics’ ThyraMIR® miRNA classifier for evaluating indeterminate thyroid nodules retroactively to January 1, 2020. This determination increases the Medicare reimbursement for ThyraMIR® from approximately $1800 to $3000 reflecting a re-evaluation of the technical

Press Release | Feb 06, 2020

Onkos Surgical® is pleased to announce the launch of GenVie™ Magnesium Bone Scaffold, a novel biologic technology that further expands Onkos’ reach in complex limb salvage procedures. GenVie is the first 510(k) cleared magnesium-based bone void filler in the orthopaedic marketplace and is available via a private label distribution agreement with Bone Solutions Inc. (OsteoCrete®)

Press Release | Feb 06, 2020

Centurion Service Group, a leader in medical equipment solutions, announced today that it has acquired Salt Lake City, UT Monet Medical, an advanced refurbisher of best-in-class beds, stretchers, infusion pumps and other medical equipment with strong ties to major national medical distributors. Originally a medical equipment auction house, Centurion Service Group has firmly cemented its

Pages 1 2 3 4 13